Abstract
As malignancy survivorship has increased, fertility preservation (FP) has become a major concern for cancer patients of reproductive age. Although embryo cryopreservation has long been the standard of care, improved technology is moving OC into the mainstream FP arena. Thus, hoping to maximize OC efficacy, we assessed pre-treatment variables & OC cycle outcomes in females newly diagnosed with malignancy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
